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Abstract Elimination of cholesterol from arterial tissue, crucial
in limiting atherogenesis, may be achieved via high-density
lipoprotein (HDL)-mediated reverse cholesterol transport
(RCT); components of this pathway can be modulated by
oxidative stress. Here we have examined the relations between
cholesterol efflux, esterification and transfer in human plasma
treated with the powerfully reactive nitrogen species, peroxyni-
trite. Cellular cholesterol efflux to whole plasma, or to
peroxynitrite-modified HDL3, was relatively insensitive to
peroxynitrite, as was the transfer of esterified cholesterol.
However, plasma cholesterol esterification, via lecithin:choles-
terol acyltransferase (LCAT), was markedly inhibited, both
directly and indirectly, by peroxynitrite treatment, implying
inefficient RCT follows HDL sequestration of cellular cholester-
ol.
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1. Introduction
Considerable epidemiological evidence has established a
strong inverse relation between levels of high-density lipopro-
tein (HDL) cholesterol and risk of coronary artery disease [1].
Multiple mechanisms may exist by which HDL protects
against premature atherosclerosis [2,3]. One proposal is that
HDL transfers excess cholesterol from peripheral tissues to
the liver for excretion, via the reverse cholesterol transport
pathway [3,4]. This pathway involves several regulated steps,
mediated by HDL apolipoproteins and two key enzymes: lec-
ithin:cholesterol acyltransferase (LCAT) and cholesteryl ester
transfer protein (CETP). E⁄cient cholesterol e¥ux from pe-
ripheral tissues requires the interaction of HDL apolipopro-
teins, and in particular apolipoprotein AI (apoAI), with spe-
ci¢c cell surface receptors [4], possibly located in membrane
caveolae [5]. ApoAI receptor-binding triggers mobilization of
intracellular stores of cholesterol, which are channelled via the
Golgi apparatus to the cell surface for e¥ux [6]. The free
cholesterol accepted by HDL undergoes esteri¢cation, via
LCAT, and most is then transferred to apolipoprotein B-con-
taining lipoproteins, by CETP, for hepatic removal [7].
Paradoxically, however, despite e⁄cient cellular e¥uxing
mechanisms, deposition of excess cholesterol still occurs with-
in arterial tissue, implying that the equilibrium between path-
ways of cholesterol deposition and removal can be perturbed.
One possible explanation is that oxidative mechanisms
thought to be associated with enhanced cholesterol deposi-
tion, via unregulated uptake of oxidized low-density lipopro-
tein by macrophage scavenger receptors, also exert negative
in£uences upon reverse cholesterol transport. Evidence exists
to support this contention: HDL oxidatively modi¢ed by cop-
per [8], irradiation [9] or aldehydic compounds extracted from
cigarette smoke [10], is a much less e⁄cient mediator of cel-
lular cholesterol e¥ux; similarly, plasma LCAT activity can
be inhibited by incubation with mildly [11], or heavily oxi-
dized LDL [12], copper ions [13] or extracts from cigarette
smoke [10,13^15]. In contrast, however, oxidative tyrosylation
of HDL results in a particle which actively promotes the mo-
bilization of cholesterol from intracellular cholesteryl ester
stores [16,17]. Further, distinct regions of apoAI mediate chol-
esterol e¥ux and LCAT activation; these can be distinguished
by mutational analysis [18], and possibly by their susceptibil-
ity to oxidative stress [10,13^15]. The e¡ects of oxidizing spe-
cies on components of the plasma reverse cholesterol trans-
port pathway are not, therefore, predictable, and may depend
on the mediating radical species.
A number of oxidizing species may exert oxidative e¡ects
within the arterial wall, including myeloperoxidase [19], 15-
lipoxygenase [20], nitric oxide [21] and superoxide [22]. Nitric
oxide (NO) and superoxide (O32 ) are both formed in the vas-
cular system by endothelial cells, neutrophils and macro-
phages [23]. Nitric oxide exerts diverse anti-in£ammatory,
and anti-atherogenic e¡ects, such as inhibition of platelet ag-
gregation [24], monocyte adhesion to the endothelium [25],
and LDL oxidation [21]; conversely, inhibition of nitric oxide
synthesis enhances the degree of atheroma formed in hyper-
cholesterolaemic rabbits [26]. However, the rapid reaction
of nitric oxide with superoxide generates a potent oxidizing
species, peroxynitrite (ONOOc) which, when protonated
(ONOOH), decomposes by complex reaction pathways result-
ing in the peroxidation of lipids [27], nitration of protein
tyrosine residues [28], oxidation of thiol groups in proteins
[29], depletion of antioxidants [30] and DNA oxidation and
nitration [31,32]. In particular, peroxynitrite can oxidize LDL
to a form which is recognized by the macrophage scavenger
receptor [33], and nitrotyrosine residues have been identi¢ed
in human atherosclerotic plaque [34,35]. Thus, peroxynitrite
may be an important cellular mediator of biological damage
in both tissue £uids, like plasma, and within the artery wall.
In this study we examine the e¡ects of peroxynitrite treat-
ment on plasma components of the reverse cholesterol trans-
port pathway, using a cellular model of cholesterol e¥ux. Our
results indicate these components exhibit di¡erential sensitiv-
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ities to peroxynitrite; in particular, plasma cholesterol ester-
i¢cation, by LCAT, appears especially susceptible to peroxy-
nitrite treatment.
2. Materials and methods
2.1. Materials
Tissue culture medium, reagents, and laboratory chemicals were
purchased from Sigma Chemical Co. (Dorset, UK), and tissue culture
plastics from Falcon (Marathon, London, UK). Puri¢ed peroxynitrite
was supplied by Alexis Co. (Nottingham, UK); immunoelectropho-
retic and agarose gels by Sebia (YSI Clandon, Hampshire, UK).
2.2. Preparation of plasma, HDL3 and LCAT
Blood samples were taken from six healthy volunteer subjects, by
collection into EDTA (0.27%, w/v), and centrifuged at 2500Ug for 30
min to remove cellular material; plasma samples were stored at
370‡C, in 1 ml aliquots, and subjected to only one freeze-thaw just
prior to peroxynitrite treatment, and subsequent use. This procedure
does not a¡ect either the cholesterol e¥uxing potential, or the LCAT
activity, of the plasma [36]. Plasma samples were treated with peroxy-
nitrite, the peroxynitrite vehicle (0.3 M NaOH) or with peroxynitrite
which had undergone decay at physiological pH; all additions were
made rapidly in a single bolus dose while vortexing the sample, as
described previously [33].
Di¡erential ultracentrifugation £otation was used to isolate HDL3
(1.125^1.26 g/ml) from freshly isolated plasma [37]. Recombinant hu-
man LCAT was isolated from the serum-free culture medium of Chi-
nese hamster ovary (CHO) cells [38], by phenyl-Sepharose chromatog-
raphy [39,40].
2.3. Analysis of lipids and apolipoproteins
Plasma total cholesterol, triacylglycerols and phospholipids were
measured using commercially available kits and standards (Sigma)
[37]; HDL cholesterol was measured following precipitation of LDL
and VLDL with phosphotungistic acid/MgCl2 [36]. Low-density lip-
oprotein (LDL) cholesterol was calculated according to the formula
described by Friedewald et al. [41]. Total apoAI was measured by
electroimmunoassay, using commercial gels (Sebia). Lipoproteins con-
taining only apoAI (LpAI) were quanti¢ed by di¡erential electroim-
munoassay (Sebia) [36]; the concentration of lipoproteins containing
both apoAI and apoAII (LpAI/AII) was calculated as the di¡erence
between total apoAI and LpAI [36].
2.4. Cell culture, lipid radiolabelling and e¥ux assay
Human THP-1 macrophages were maintained exactly as described
[37]; for experiments cells were seeded at 1U106/well into 12-well
plates, containing RPMI 1640 medium supplemented with glutamine
(4 mM), penicillin (20 IU/ml) and streptomycin (20 Wg/ml), bovine
fetal calf serum (10%, v/v) and phorbol 12-myristate 13-acetate
(PMA) (100 ng/ml). Cells were maintained for 5 days; media contain-
ing PMA were replaced at 2 day intervals.
Cholesterol e¥ux from THP-1 macrophages was performed exactly
as described [36]; this method has been fully characterized for Fu5AH
cells [36], and is increasingly being employed to measure cholesterol
e¥ux from other cell types [42,43]. Brie£y, [3H]cholesterol (1 WCi/well;
¢nal concentration 0.1% ethanol) was added to macrophages in
RPMI medium containing fetal calf serum (5%); macrophages were
incubated in this medium for 24 h. Cells were then incubated in RPMI
medium containing bovine serum albumin (1%) for a further 18 h,
prior to measuring cholesterol e¥ux.
The e¥ux potential of each plasma sample was assayed by incubat-
ing human plasma (5% by vol.) with triplicate wells of labelled macro-
phages, at 37‡C for 4 h. Alternatively, where isolated HDL3 was used
as the cholesterol acceptor, the cells were incubated with RPMI me-
dium containing bovine serum albumin (1%), and the appropriate
concentrations of HDL3. Medium was removed from the cells, and
centrifuged at 10 000Ug to remove any £oating cells ; released choles-
terol was measured in an aliquot of the medium by scintillation count-
ing. Residual medium was stored at 370‡C for further analysis; mac-
rophages were washed three times with cold phosphate-bu¡ered saline
(PBS), and cellular lipids extracted by addition of isopropanol, over-
night at room temperature. The fractional cholesterol e¥ux was cal-
culated as the amount of label released to the medium, divided by the
total label in each well [36].
2.5. Measurement of cholesterol esteri¢cation
Cholesterol esteri¢cation, in the e¥ux medium containing test sam-
ples of human plasma, was assayed by measuring the proportion of
labelled cellular cholesterol which became esteri¢ed in the medium
during the e¥ux phase. Medium lipids were extracted by the method
of Bligh and Dyer [44], the extract dried under N2, and free choles-
terol and cholesteryl esters separated by thin layer chromatography
(t.l.c.), using hexane:diethyl ether:glacial acetic acid (90/20/1, by vol.)
as the mobile phase. Preliminary experiments con¢rmed that, as in
Fu5AH cells [36], the bulk of cellular cholesterol in the macrophages
was unesteri¢ed, and only free cholesterol was released to acceptors in
the culture medium.
Plasma LCAT activity was determined using an exogenous proteo-
liposome substrate of [14C]cholesterol, egg lecithin and apoAI, as
described previously [38,45]. Incubation time was 1 h at 37‡C, or as
appropriate, and the production of [14C]cholesteryl ester measured by
t.l.c., as above. Alternatively, in some experiments the e¡ect of per-
oxynitrite on endogenous LCAT substrate was investigated using hu-
man recombinant LCAT as the enzyme source. In this case, heat-
inactivated plasma was incubated with [3H]cholesterol/human serum
albumin (HSA) complex, exactly as described [46], before the addition
of human recombinant LCAT, and incubation for a further 1 h at
37‡C. Percentage conversions of substrate to radiolabelled cholesteryl
ester were determined by t.l.c., as before.
2.6. Transfer of e¥uxed cellular cholesterol to LDL/VLDL
The distribution of [3H]cholesteryl esters between HDL and
apoB100-containing lipoproteins was used as an estimate of choles-
teryl ester transfer protein (CETP) activity in the e¥ux medium.
ApoB lipoproteins were precipitated from the e¥ux medium by treat-
ment with phosphotungistic acid (0.4%) and MgCl2 (0.2 M) (¢nal
concentrations); samples were vortexed, and placed on ice for 10
min, before centrifugation at 10 000Ug [36]. Pellets were washed
with PBS containing phosphotungistic acid/MgCl2 mixture (as above)
and lipids extracted by the method of Bligh and Dyer [44]. Cholesterol
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Table 1
Average parameters of test plasma samples
Parameter Mean þ S.D. (Range)
Total cholesterol, mmol/l 4.48 þ 1.45 (2.51^6.71)
Triacylglycerol, mmol/l 1.48 þ 1.09 (0.46^3.34)
Phospholipids, mmol/l 2.72 þ 0.47 (1.94^3.32)
HDL cholesterol, mmol/l 0.86 þ 0.25 (0.50^1.27)
LDL cholesterol, mmol/l 2.95 þ 1.09 (1.26^4.40)
Apolipoprotein AI, g/l 1.13 þ 0.20 (0.82^1.34)
LpAI, g/l 0.55 þ 0.16 (0.38^0.81)
LpAII, g/l 0.58 þ 0.20 (0.42^0.86)
Fractional cholesterol e¥ux/h (%) 6.27 þ 2.04% (4.11^9.46)
Cholesterol esteri¢cation (%) 2.49 þ 0.37% (1.96^3.06)
Cholesterol ester transfer (%) 0.51 þ 0.17% (0.30^0.81)
Sample measurements were performed as outlined in Section 2; values given are means þ S.D. (n = 6).
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and cholesteryl esters were separated by t.l.c., as described above;
values were expressed as a percentage of the total cholesterol e¥uxed,
and of the total cholesterol esteri¢ed in the medium.
2.7. Statistics
All results are expressed as means þ S.D., or as means þ ranges;
statistical di¡erences (P6 0.05) were determined by Student’s two-
tailed t-test.
3. Results
3.1. Cholesterol e¥ux from human (THP-1) macrophages
Measurement of cholesterol e¥ux and subsequent esteri¢-
cation and transfer reactions, were performed using human
(THP-1) macrophages, radiolabelled with [3H]cholesterol
(Section 2) and incubated with samples of plasma (5%) iso-
lated, and characterized, from six healthy volunteers (Table
1). Although the e¥ux of cholesterol is lower in macrophages
than other cell types [36], our values for fractional esteri¢ca-
tion, and subsequent transfer to LDL, of cell-derived choles-
terol are in good agreement with published values [36].
Addition of peroxynitrite (1 mM) to human plasma did not
signi¢cantly alter the total e¥ux of [3H]cholesterol from THP-
1 macrophages; higher levels (5 mM) resulted in only a 30%
reduction in e¥ux (P6 0.05) (Fig. 1A). This insensitivity to
peroxynitrite implied either (a) an inherent resistance of HDL
to modi¢cation by peroxynitrite, or (b) that plasma constitu-
ents may be protecting against peroxynitrite modi¢cation. To
distinguish between these possibilities, we incubated radiola-
belled THP-1 macrophages with isolated HDL3, following the
direct modi¢cation of this lipoprotein with peroxynitrite. In-
creases in HDL3 relative electrophoretic mobility on agarose
gels (1.25 þ 0.05, n = 3, mean þ S.D.) and in thiobarbituric acid
reactive substances (6.97 þ 0.63 nmol/mg HDL3, n = 2,
mean þ range) were observed for HDL3 (1 mg/ml) treated
with peroxynitrite (1 mM). Modi¢cation of HDL by peroxy-
nitrite (0.5^5 mM) is associated with polymerization of apoAI
and nitration of tyrosine residues [47]. These evident changes
in HDL structure and composition were accompanied by de-
creased cholesterol e¥ux from THP-1 macrophages (Fig. 1B);
the maximal decrease achieved was around 40% (1 mM per-
oxynitrite). Therefore, it seems likely that plasma proteins and
antioxidants protect HDL against modi¢cation by peroxyni-
trite [30] ; in support of this, no changes in the electrophoretic
mobility of plasma lipoproteins were observed following per-
oxynitrite treatment (data not shown).
3.2. Cholesterol esteri¢cation in human plasma
Cholesterol released from human (THP-1) macrophages to
acceptors in human plasma (5%), undergoes transesteri¢cation
via LCAT. In contrast to cholesterol e¥ux, esteri¢cation in
plasma-containing tissue culture medium was markedly inhib-
ited (s 65%, P6 0.005) by the addition of peroxynitrite (1
mM or higher) (Fig. 2A). No inhibition was noted with per-
oxynitrite which had been allowed to decay at physiological
pH, before addition to the plasma sample at a concentration
equivalent to 5 mM peroxynitrite. As the esteri¢cation of
e¥uxed [3H]cholesterol was strikingly reduced, we pursued
this ¢nding by measuring LCAT activity in plasma treated
with peroxynitrite (Fig. 2B, C). This involves the addition of
plasma (7.5 Wl) to an arti¢cial proteoliposome substrate (0.24
ml) [38,45] labelled with [14C]cholesterol ; essentially, there-
fore, plasma LCAT activity is assayed under optimized con-
ditions, in the presence of an intact, non-oxidized, substrate.
Results from the cellular cholesterol e¥ux studies were con-
¢rmed: plasma LCAT activity is dose-dependently inhibited
by peroxynitrite (IC50 = 0.75 mM) (Fig. 2B) at all time points
assayed (Fig. 2C), in two independent experiments using dif-
ferent plasma samples. Additional controls monitored the ef-
fects of adding either the peroxynitrite vehicle (0.3 M NaOH),
or decayed peroxynitrite (Fig. 2B): non-speci¢c e¡ects on
LCAT activity were not detected.
These experiments indicate that peroxynitrite treatment of
plasma results in direct inhibition of LCAT activity. We con-
¢rmed this ¢nding by treating human recombinant LCAT
[38^40] directly with peroxynitrite, and measuring activity us-
ing the proteoliposome substrate; total inhibition of LCAT
activity was achieved at 0.5 mM (data not shown). Neverthe-
less, we examined the e¡ect of peroxynitrite on the ability of
plasma to sustain exogenous LCAT activity. Heat-inactivated
human plasma was equilibrated with [3H]cholesterol, and
treated with peroxynitrite (0^5 mM), before the addition of
human recombinant LCAT [38^40,46] (Fig. 2D). Recombi-
nant LCAT activity was decreased by about 40% in plasma
treated with peroxynitrite (1 mM), suggesting modi¢cation of
the endogenous LCAT substrate contributes to LCAT inhib-
ition or inactivation.
3.3. Cholesteryl ester transfer in human plasma
The fractional conversion of cell-derived [3H]cholesterol
into cholesteryl ester is followed by the subsequent transfer
of [3H]cholesteryl esters from HDL to LDL and VLDL, via
the action of CETP. As expected, [3H]cholesteryl esters trans-
ferred to LDL/VLDL decreased substantially following per-
oxynitrite treatment, when expressed as a percentage of the
total cholesterol e¥ux (Fig. 3A), re£ecting the marked inhib-
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Fig. 1. A: Cellular e¥ux of cholesterol to plasma acceptors. Macro-
phages were pre-labelled with [3H]cholesterol in the absence (1%
BSA) or presence of plasma samples (5%), treated with the indi-
cated concentrations of peroxynitrite. Values are means þ S.D. of six
plasma samples; ** indicates values signi¢cantly di¡erent (P6 0.05)
from both the control incubation, and from plasma treated with
1 mM peroxynitrite. Results were con¢rmed in a second independ-
ent experiment. B: Cellular cholesterol e¥ux to peroxynitrite-modi-
¢ed HDL3. Macrophages were incubated (Section 2) in the presence
of isolated HDL3 (a), modi¢ed by the addition of peroxynitrite (0.5
mM (b) ; 1 mM (F)). Values are means þ S.D. of triplicate wells in
a single representative experiment; values were con¢rmed in three
further independent experiments.
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ition of LCAT activity in these samples (Fig. 2A). However,
when LDL/VLDL-[3H]cholesteryl ester is expressed as a per-
centage of total [3H]cholesteryl ester, it is evident a greater
percentage of esteri¢ed cholesterol is entering the LDL/VLDL
pool (Fig. 3B). This suggests CETP activity is not inhibited by
peroxynitrite treatment of plasma; indeed, at higher concen-
trations a greater overall proportion of cholesteryl ester is
transferred to LDL/VLDL.
4. Discussion
Reverse cholesterol transport, mediated by the interactions
of HDL, LCAT and CETP, is a major way to eliminate chol-
esterol from peripheral tissues. Our study suggests that per-
oxynitrite, a reactive nitrogen species implicated in atherogen-
esis [34,35], has the potential to modulate this process. The
e¥ux of cholesterol to plasma acceptors is only slightly re-
duced at high concentrations of peroxynitrite; this appears
due to the protective e¡ect of plasma constituents, as HDL
is not inherently resistant to peroxynitrite modi¢cation. In
contrast, plasma esteri¢cation of cholesterol, via LCAT, is
markedly inhibited at much lower concentrations of peroxy-
nitrite ; inhibition appears to be exerted by both direct, and
indirect, e¡ects on the enzyme activity. As established else-
where [48], endogenous LCAT activity does not determine
the rate of cellular cholesterol e¥ux; rather, the conversion
of cholesterol to cholesteryl ester by LCAT is thought to
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Fig. 2. A: Esteri¢cation of e¥uxed cholesterol. Esteri¢cation of e¥uxed cholesterol in plasma exposed to peroxynitrite (ONOO3) or decayed
peroxynitrite (ONOOc control). Values are means þ S.D. of six plasma samples; * indicates values signi¢cantly di¡erent (P6 0.05) from control
plasma; ** indicates values signi¢cantly di¡erent (P6 0.05) from both the control, and from plasma treated with 1 mM peroxynitrite. Results
were con¢rmed in a further independent experiment. B: Plasma LCAT activity. Esteri¢cation of cholesterol in plasma exposed to varying con-
centrations of peroxynitrite (b), its vehicle (a) or decayed peroxynitrite (E), measured using an exogenous proteoliposome substrate (Section 2).
Values are the means þ S.D. of triplicate measurements. C: Plasma LCAT activity. Esteri¢cation of cholesterol in plasma, in the absence (a) or
presence of 0.5 mM (b), 1 mM (F) or 5 mM (R) peroxynitrite, measured using an exogenous proteoliposome substrate (Section 2). Values are
means þ S.D. of incubations performed in triplicate. D: Human recombinant LCAT activity in peroxynitrite-modi¢ed plasma. Esteri¢cation of
cholesterol, by human recombinant LCAT, in heat-inactivated, [3H]cholesterol-labelled plasma treated with varying concentrations of peroxyni-
trite (Section 2). Values are means þ ranges of duplicate incubations.
Fig. 3. Transfer of cholesteryl ester to LDL/VLDL. Transfer of ef-
£uxed, and esteri¢ed, cholesterol to LDL/VLDL, expressed as a per-
centage of total cholesterol e¥ux (A) or as a percentage of esteri¢ed
cholesterol (B). Values are means þ S.D. of six plasma samples; * in-
dicates values signi¢cantly di¡erent (P6 0.05) from control plasma;
** indicates values signi¢cantly di¡erent (P6 0.05) from both con-
trol plasma, and from plasma treated with 1 mM peroxynitrite. Re-
sults were con¢rmed in a further independent experiment.
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reduce the ‘back-transfer’ of cholesterol from HDL to the
macrophages. The subsequent transfer of cholesteryl ester to
the LDL/VLDL plasma fraction is also decreased, but as a
result of LCAT inhibition and not, apparently, to inhibition
of CETP. Overall, therefore, generation of peroxynitrite
would be predicted to decrease the e⁄ciency of the plasma
reverse cholesterol transport pathway, predominantly by in-
hibition of LCAT activity.
The biological signi¢cance of our ¢ndings may not be im-
mediately apparent, given the high concentrations of peroxy-
nitrite employed. However, the short half-life (6 1 s) of this
oxidant at physiological pH means that a bolus dose of 1 mM
peroxynitrite is equivalent to an exposure of 26 WM min31
[30,49]. Thus, it is not the absolute concentration, but rather
the e¡ective exposure (concentrationUexposure time) that de-
termines the e¡ect of peroxynitrite treatment [30,49]. Further-
more, formation of peroxynitrite at rates of 0.1 nmol/106 cells/
min is reported for activated murine macrophages [50] and
human neutrophils [51], leading to suggestions that local con-
centrations of peroxynitrite may rise as high as 0.5^1.0 mM
min31 under certain pathological conditions [50]. The inhib-
ition of LCAT activity by peroxynitrite could potentially,
therefore, be important during in£ammation in vivo. Indeed,
LCAT activity and/or expression, are decreased during the
acute phase response in animal models [52], following cyto-
kine-induced hyperlipidaemia [53], and in human patients in-
fected with Schistosomiasis mansoni [54]; decreased LCAT
activity has also been noted in patients with diabetes mellitus
[55] and coronary artery disease [56].
The precise mechanism by which peroxynitrite inhibits
LCAT activity has not been the focus of this study; never-
theless, our results indicate that LCAT activity can be inhib-
ited directly by this reactive species. In particular, both plas-
ma LCAT activity and human recombinant LCAT is
inhibited by peroxynitrite, when assessed using an intact pro-
teoliposome substrate. Similar results have been described for
the e¡ect of aldehydes isolated from the gas phase of cigarette
smoke [10,13^15]. Inhibition of LCAT by aldehydes is inde-
pendent of lipid peroxidation, protected by N-acetyl cysteine
and reversible by disulphide-reducing agents [13^15]; these
results indicate that covalent modi¢cation of free thiol groups
Cys-31 and Cys-184, near the active site of the enzyme, inhib-
its LCAT activity [13^15]. Free thiol groups are an obvious
target for peroxynitrite attack [29,49]; alternatively, however,
LCAT contains a number of tyrosine residues, which may
undergo nitration and possibly a¡ect LCAT activity [28]. In-
deed, a naturally occurring LCAT mutation, Tyr156Asn, de-
creases the activity of LCAT by around 70%, possibly via an
disturbed enzyme-lipid interaction [57].
However, plasma LCAT may also be inhibited indirectly by
peroxynitrite treatment. Plasma treated with peroxynitrite ap-
pears to be a less e¡ective substrate for human recombinant
LCAT; this could be, of course, due either to modi¢cation of
the LCAT substrate, or to the formation of an inhibitory
species within the plasma. LCAT can be inhibited by mildly
[11] and heavily oxidized LDL [12], and by lipid peroxides
[13]; oxidation of plasma, by copper or peroxyl radicals,
also leads to apoAI and apoAII crosslinking, which can ab-
rogate LCAT activation [13,58]. Our evidence suggests that
plasma HDL is relatively resistant to functional modi¢cation
by peroxynitrite; equally, only trace amounts of cholesteryl
ester hydroperoxides have been detected following peroxyni-
trite treatment of plasma [30]. The latter suggests lipid peroxi-
dation is not the major route by which peroxynitrite modi¢es
the ability of plasma to support LCAT activity; our prelimi-
nary evidence also indicates that treatment of peroxynitrite-
modi¢ed plasma with Ebselen to reduce lipid hydroperoxides
does not restore LCAT activity (data not shown). However,
plasma LDL does exhibit increased levels of nitrotyrosine
following peroxynitrite treatment [28]. Thus, multiple mecha-
nisms may exist by which peroxynitrite modi¢es LCAT activ-
ity, which require further study.
This study indicates that peroxynitrite can inhibit the activ-
ity of a key component of the reverse cholesterol pathway.
However, the implications of LCAT inhibition for atherogen-
esis are not, as yet, entirely clear, mainly because the protec-
tive role of LCAT in atherosclerotic vascular disease is not
established. Studies in transgenic animal models have indi-
cated that over-expression of human LCAT induces hyper-
alphaproteinaemia, and a less atherogenic lipoprotein pro¢le,
in both mice [59] and rabbits [60] ; paradoxically, however,
LCAT over-expression can either exacerbate [61], or protect
against [62] development of atherosclerosis in these animal
models. In man, LCAT de¢ciency causes HDL de¢ciency,
elevated triacylglycerol levels, and clinical symptoms of cor-
neal opaci¢cation, anaemia, proteinuria and renal disease, but
not overt premature atherosclerosis [63]. An unequivocal dem-
onstration of the protective role of LCAT in atherogenesis
therefore remains elusive.
In summary, therefore, we have demonstrated that peroxy-
nitrite can modify components of the plasma reverse choles-
terol transport pathway, and that LCAT activity is particu-
larly susceptible to attack by this reactive species. The precise
mechanism, and physiological signi¢cance, of LCAT inhibi-
tion by peroxynitrite will be the subject of future studies.
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